Get Free Consultation

Email Us:  support@cspanresearchsol.com

Head Office +91 8729085230

Guru Angad Nagar,
New Delhi 110092

09.00 to 18.00 Monday to Saturday

Industry Detail
  • Home
  • Industry Detail

Market Overview:

Global Cell Line Development Market is expected to offer an $ opportunity of USD 10,149.30 million over the forecast period. 

Global Cell Line Development Market size is expected to surpass USD 14,832.5 million by the end of 2031, growing at a CAGR of 13.45% over the forecast period, i.e., 2022 – 2031. In the year 2021, the industry size of Cell Line Development was USD 4,683.2 Million. 

Base Year2021
Forecast Year2022-2031
CAGR13.45%
Base Year Market Size (2021)USD 4,683.2 Million
Forecast Year Market Size (2031)USD 14,832.5 Million

Throughout the long term, the biopharmaceutical market has developed into a promising, high worth vertical inside the general drug industry. Truth be told, almost 29% and 25% of the complete number of novel medications endorsed by the Food and Medication Organization's Middle for Medication Assessment and Exploration (CDER) in 2018 and 2019, separately, were biologics. 

Subsequently, the pipeline of biologics and biosimilars is developing at an estimable speed. Considering that the turn of events and assembling of such treatments require living natural frameworks, there has been a flood popular for various sorts of cell lines. As a matter of fact, around 84% of the remedial proteins showcased over the most recent five years, were created utilizing different mammalian and microbial cells. 

Given the cost intensive nature of pharmacological R&D, medical researchers / drug developers are consistently on the lookout for ways to optimize operational efficiencies, as well as reduce affiliated costs; in this context, outsourcing has emerged as a preferred business model. Presently, there are several contact service providers that claim to have the necessary expertise to develop and characterize cell lines. The technical aspect of this field is also witnessing a lot of innovation, especially with regard to automating various steps of the cell line development process. 

New genome editing technologies, such as the CRISPR/Cas-9, are also being extensively used to improve the quality of recombinant cell lines. Unlike drug developers, the capabilities of service providers are usually more focused to their respective service portfolios. 

Moreover, such companies ensure that they have the latest upgrades in equipment and infrastructure, in order to improve the quality of services offered. In fact, in the recent past, a number of service providers offering cell lines-related services, have forged strategic alliances with and / or acquired other players, in order to further enhance their respective portfolios. Considering the growing trend of outsourcing and the ongoing efforts of service providers to improve / expand their offerings, we believe the contract services market for cell line development and characterization is likely to evolve at a steady pace, till 2030.

Market Dynamics: The growth primarily attributed to the factors such as:

Growth Enablers:

  • Growing demand for bispecific and monoclonal antibodies (mAbs)
  • Recombinant proteins and vaccines needed to treat oncological, autoimmune and infectious diseases
  • Technological advancements in cell line engineering and development, as well as emerging screening techniques and process development paradigms, are also set to fuel growth opportunities for the market.

Challenges Associated with the CLD Market: 

  • Development of stable cell lines
  • Increased risk of contamination in upstream and downstream processes

Regional Market Outlook:

Currently, North America is accounted for the largest share in the global market, owning to higher demand for novel and targeted medicine accompanied with growing R&D activities in the region. NA id accounted for almost 36.75% of total global market share followed by Europe. Asia-Pacific is growing at a 15.76% CAGR during the projected timeframe. At institution-level, research activities are at higher end.

Addressing Challenges: Contract development and manufacturing organisations (CDMOs) can shorten commercial timelines and increase programme efficiencies without sacrificing product quality or yield, by understanding and using best practices.

Our report has covered several other key aspects pertaining to market:

  • What is the need to strategically accelerate CLD?
  • Strategies for a robust CLD programme?
  • Steps for identifying the best cell line for efficient antibody CLD?
  • Techniques for accelerating CHO CLD?

Strategic Developments in the Market:

  •  ProBioGen and Thermo Fisher Scientific collaboratively developed a cell-line development kit called Gibco™ Freedom™ ExpiCHO-S™ Cell Line Development Kit

Competitive Landscape:

  • A company competitiveness analysis, highlighting prominent cell line development service providers based in different regions, taking into consideration their supplier strength (experience of the service provider), and portfolio specifications (sources of cell lines and expression systems handled, availability of proprietary / licensed technology platform, type of gene expression and availability of additional cell line related services).
  • Elaborate profiles of cell line development service providers. Each company profile features a brief overview of the company, its financial information (if available), cell line development and complementary services portfolio and an informed future outlook.
  • Company such as SARTORIUS is offering wide portfolio of CLD instruments, CLD services and CLD Custom solutions 

Market Segmentation:

Our in-depth analysis of the Global Cell Line Development Market includes the following segments:

Global Cell Line Development Market
Base Year:2021Forecast Period:2022-2031
Historical Data:2021Market Size in 2021:USD 4,683.2 Million
Forecast Period 2022-35 CAGR:13.45%Market Size in 2031:USD 14,832.50 Million
Segments Covered:By Product

 

  • Equipment
  • Media and Reagents
By Industry
  • Biotechnology
  • Biopharma
  • Academia
By Cell Type
  • CHO Cells
  • BHK 21 Cells
  • NSO Cells
  • Murine C127 Cells
  • NIH3T3 Cells
  • L929 Cells
  • Other Cells
By Application
  • Bioproduction 
  • Tissue Engineering
  • Regenerative Medicine
  • Biologics
  • Medicines
  • Toxicity Testing
  • Research
  • Drug Discovery
  • Cell Therapies
  • Gene Therapies
By Region
  • North America (U.S., Canada)
  • Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Poland, Netherlands, Rest of Europe)
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Saudi Arabia, Israel, UAE, South Africa, Rest of MEA)
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America)
Key Market Drivers:
  • Rising demand for monoclonal antibodies
  • Rising need for vaccine production
  • Rising Demand at Institution-level
Key Market Restraints:
  • Development of a stable and authentic cell lines
Key Trends:
  • Tapping emerging market
  • Fulfilling market unmet need
Companies Covered in the Report:
  • BIO-RAD
  • Biocompare
  • Catalent BIOLOGICS
  • Lonza Group AG
  • Thermo Fisher Scientific, Inc.
  • Cytiva
  • MOLECULAR DEVICES
  • Corning Inc.
  • 908 devices
  • GE healthcare
  • Sartorius AG
  • Selexis SA
  • Sigma-Aldrich Corporation
  • Wuxi Apptec
  • Other players

Academic Profiles

  • American Type Culture Collection (ATCC)
  • European Collection of Cell Culture

Recent Developments in the Market:

  • April 2022: Molecular Devices LLC has been continuing its investment since April 2021 in Organoid Innovation Center, adding cell engineering capabilities to an automated 3D cell culture platform.
  • Oct. 2023: Molecular Devices Introduces CellXpress.ai Automated Cell Culture System, a 3D Biology Innovation Hub for Fast, Reliable Drug Discoveries 
  • December 2021: DenovoMATRIX launched its new product, isoMATRIX, a high-yield MSC isolation technology for cell and gene therapy. It has the efficiency to get nearly 35% more stem cells with better quality and faster growth.

Place An Order

Related Reports